Cambridge, MA, United States of America

Richard Vargas

This inventor holds 4 USPTO granted patents and 4 published patent applications. Top assignee: Blueprint Medicines Corporation. Active years: 2024-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard Vargas. Retrieved from https://idiyas.com/inventor/richard-vargas-37k64d2o

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 

% Patents Active = 75.0

Average Co-Inventor Count = 7.3

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2024-2026

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Richard Vargas: Innovator in Cancer Treatment

Introduction

Richard Vargas is a notable inventor based in Cambridge, MA. He has made significant contributions to the field of cancer treatment through his innovative work. With a total of 4 patents, Vargas is recognized for his dedication to advancing medical science.

Latest Patents

Vargas's latest patents focus on CDK2 inhibitors. The present disclosure provides a compound represented by structural Formula (I) or a pharmaceutically acceptable salt thereof, which is useful for treating cancer. This innovative approach aims to enhance the effectiveness of cancer therapies.

Career Highlights

Richard Vargas is currently employed at Blueprint Medicines Corporation. His work at this esteemed organization has allowed him to collaborate with other talented professionals in the field. His contributions have been instrumental in the development of new therapeutic strategies.

Collaborations

Some of his notable coworkers include Douglas Wilson and Neil Bifulco. Their combined expertise fosters a collaborative environment that drives innovation in cancer research.

Conclusion

In summary, Richard Vargas is a dedicated inventor whose work in developing CDK2 inhibitors is paving the way for new cancer treatments. His contributions to Blueprint Medicines Corporation and collaborations with esteemed colleagues highlight his commitment to advancing medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…